New psoriasis ointment shows promise in large chinese trial

NCT ID NCT05919082

Completed Disease control Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

First seen Apr 17, 2026 · Last updated May 25, 2026 · Updated 9 times

Summary

This study tested a new ointment (LEO 90100) against a standard one (Daivobet) in 604 Chinese adults with stable plaque psoriasis. Participants applied the treatment for 4 weeks. The goal was to see which ointment better cleared or nearly cleared psoriasis patches on the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

LEO Pharma Investigational Site

Bengbu, Anhui, 233060, China
LEO Pharma Investigational Site

Hefei, Anhui, 230022, China
LEO Pharma Investigational Site

Beijing, Beijing Municipality, 100044, China
LEO Pharma Investigational Site

Beijing, Beijing Municipality, 100050, China
LEO Pharma Investigational Site

Chongqing, Chongqing Municipality, 400021, China
LEO Pharma Investigational Site

Chongqing, Chongqing Municipality, 400042, China
LEO Pharma Investigational Site

Guangzhou, Guangdong, 510080, China
LEO Pharma Investigational Site

Guangzhou, Guangdong, 516006, China
LEO Pharma Investigational Site

Shenzhen, Guangdong, 518020, China
LEO Pharma Investigational Site

Cangzhou, Hebei, 061000, China
LEO Pharma Investigational Site

Chengde, Hebei, 067000, China
LEO Pharma Investigational Site

Shijiangzhuang, Hebei, 050030, China
LEO Pharma Investigational Site

Nanyang, Henan, 473004, China
LEO Pharma Investigational Site

Shiyan, Hubei, 442000, China
LEO Pharma Investigational Site

Wuhan, Hubei, 430022, China
LEO Pharma Investigational Site

Changsha, Hunan, 410011, China
LEO Pharma Investigational Site

Baotou, Inner Mongolia, 014010, China
LEO Pharma Investigational Site

Baotou, Inner Mongolia, 014016, China
LEO Pharma Investigational Site

Hohhot, Inner Mongolia, 010000, China
LEO Pharma Investigational Site

Wuxi, Jiangsu, 214002, China
LEO Pharma Investigational Site

Yangzhou, Jiangsu, 225003, China
LEO Pharma Investigational Site

Zhenjiang, Jiangsu, 212001, China
LEO Pharma Investigational Site

Changchun, Jilin, 130021, China
LEO Pharma Investigational Site

Xi'an, Shaanxi, 510080, China
LEO Pharma Investigational Site

Dongying, Shandong, 257099, China
LEO Pharma Investigational Site

Jinan, Shandong, 250013, China
LEO Pharma Investigational Site

Jinan, Shandong, 250022, China
LEO Pharma Investigational Site

Shanghai, Shanghai Municipality, 200443, China
LEO Pharma Investigational Site

Chengdu, Sichuan, 610044, China
LEO Pharma Investigational Site

Suining, Sichuan, 629000, China
LEO Pharma Investigational Site

Hangzhou, Zhejiang, 310003, China
LEO Pharma Investigational Site

Hangzhou, Zhejiang, 310009, China
LEO Pharma Investigational Site

Hangzhou, Zhejiang, 310014, China
LEO Pharma Investigational Site

Hangzhou, Zhejiang, 310016, China
LEO Pharma Investigational Site

Jiaxing, Zhejiang, 314001, China
LEO Pharma Investigational Site

Ningbo, Zhejiang, 315010, China
LEO Pharma Investigational Site

Ningbo, Zhejiang, 315016, China
LEO Pharma Investigational Site

Wenzhou, Zhejiang, 325000, China

Conditions

Explore the condition pages connected to this study.

STABLE PLAQUE PSORIASIS